Mesoblast Ltd
MESO15.950USD
-0.130-0.81%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
2.04BCap. mercado
PérdidaP/E TTM
Más Datos de Mesoblast Ltd Compañía
Mesoblast Limited is an Australia-based company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company’s Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: chronic heart failure (chf) and chronic low back pain (clbp) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.
Información de Mesoblast Ltd
Símbolo de cotizaciónMESO
Nombre de la empresaMesoblast Ltd
Fecha de salida a bolsaDec 16, 2004
Director ejecutivoItescu (Silviu)
Número de empleados81
Tipo de seguridadDepository Receipt
Fin del año fiscalDec 16
DirecciónL 38 55 Collins St
CiudadMELBOURNE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísAustralia
Código postal3000
Teléfono61396396036
Sitio Webhttps://www.mesoblast.com/
Símbolo de cotizaciónMESO
Fecha de salida a bolsaDec 16, 2004
Director ejecutivoItescu (Silviu)
Ejecutivos de Mesoblast Ltd
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Eric A. Rose, M.D.
Dr. Eric A. Rose, M.D.
Executive Director, Chief Medical Officer
Executive Director, Chief Medical Officer
71.47K
+30310.00%
Dr. Silviu Itescu
Dr. Silviu Itescu
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. William M. (Bill) Burns
Mr. William M. (Bill) Burns
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Mr. Peter Howard
Mr. Peter Howard
General Counsel, Corporate Executive
General Counsel, Corporate Executive
--
--
Ms. Geraldine Storton
Ms. Geraldine Storton
Head - Regulatory Affairs and Quality Management
Head - Regulatory Affairs and Quality Management
--
--
Ms. Niva Sivakumar
Ms. Niva Sivakumar
Joint Company Secretary
Joint Company Secretary
--
--
Mr. Philip J. (Phil) Facchina
Mr. Philip J. (Phil) Facchina
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Justin Horst, Ph.D.
Mr. Justin Horst, Ph.D.
Head - Manufacturing
Head - Manufacturing
--
--
Mr. Michael Schuster
Mr. Michael Schuster
Pharma Partnering
Pharma Partnering
--
--
Mr. Philip R. Krause, M.D.
Mr. Philip R. Krause, M.D.
Non-Executive Non-Independent Director
Non-Executive Non-Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Eric A. Rose, M.D.
Dr. Eric A. Rose, M.D.
Executive Director, Chief Medical Officer
Executive Director, Chief Medical Officer
71.47K
+30310.00%
Dr. Silviu Itescu
Dr. Silviu Itescu
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. William M. (Bill) Burns
Mr. William M. (Bill) Burns
Non-Executive Independent Vice Chairman of the Board
Non-Executive Independent Vice Chairman of the Board
--
--
Mr. Peter Howard
Mr. Peter Howard
General Counsel, Corporate Executive
General Counsel, Corporate Executive
--
--
Ms. Geraldine Storton
Ms. Geraldine Storton
Head - Regulatory Affairs and Quality Management
Head - Regulatory Affairs and Quality Management
--
--
Ms. Niva Sivakumar
Ms. Niva Sivakumar
Joint Company Secretary
Joint Company Secretary
--
--
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: jue., 5 de feb
Actualizado: jue., 5 de feb
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Gueck (William J)
4.97%
Legal & General Investment Management Ltd.
0.50%
Morgan Stanley & Co. International Plc
0.32%
Goldman Sachs & Company, Inc.
0.32%
BlackRock Institutional Trust Company, N.A.
0.29%
Otro
93.59%
Accionistas
Accionistas
Proporción
Gueck (William J)
4.97%
Legal & General Investment Management Ltd.
0.50%
Morgan Stanley & Co. International Plc
0.32%
Goldman Sachs & Company, Inc.
0.32%
BlackRock Institutional Trust Company, N.A.
0.29%
Otro
93.59%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
5.06%
Investment Advisor
1.45%
Research Firm
0.83%
Investment Advisor/Hedge Fund
0.68%
Hedge Fund
0.02%
Venture Capital
0.01%
Otro
91.94%
Participación institucional
Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
140
3.87M
3.00%
-443.29K
2025Q3
134
3.48M
2.71%
-1.10M
2025Q2
126
4.04M
3.16%
+542.30K
2025Q1
132
4.07M
3.19%
+9.28K
2024Q4
122
3.23M
2.55%
+620.09K
2024Q3
100
1.76M
1.52%
-1.23M
2024Q2
98
1.70M
1.52%
-705.91K
2024Q1
97
1.24M
1.12%
-806.95K
2023Q4
94
840.17K
0.85%
-1.02M
2023Q3
97
766.21K
0.94%
-1.35M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Gueck (William J)
6.42M
5%
+6.42M
--
Sep 12, 2025
Legal & General Investment Management Ltd.
651.42K
0.51%
+651.42K
--
Sep 30, 2025
Morgan Stanley & Co. International Plc
413.52K
0.32%
+100.00K
+31.90%
Sep 30, 2025
Goldman Sachs & Company, Inc.
407.28K
0.32%
-8.19K
-1.97%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
376.17K
0.29%
-122.83K
-24.61%
Sep 30, 2025
Susquehanna International Group, LLP
271.49K
0.21%
+36.90K
+15.73%
Sep 30, 2025
Arax Advisory Partners
200.08K
0.16%
+200.08K
--
Sep 30, 2025
Summit Wealth Strategies
199.29K
0.16%
+1.13K
+0.57%
Jun 30, 2025
Aperio Group, LLC
137.23K
0.11%
+2.06K
+1.52%
Sep 30, 2025
BofA Global Research (US)
111.46K
0.09%
+98.96K
+791.74%
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: mar., 2 de dic
Actualizado: mar., 2 de dic
Nombre
Proporción
iShares Biotechnology ETF
0.1%
Invesco Nasdaq Biotechnology ETF
0.08%
ProShares Ultra Nasdaq Biotechnology
0.08%
ActivePassive International Equity ETF
0.01%
iShares Biotechnology ETF
Proporción0.1%
Invesco Nasdaq Biotechnology ETF
Proporción0.08%
ProShares Ultra Nasdaq Biotechnology
Proporción0.08%
ActivePassive International Equity ETF
Proporción0.01%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Dec 22, 2023
Merger
2→1
Dec 22, 2023
Merger
2→1
Dec 22, 2023
Merger
2→1
Dec 22, 2023
Merger
2→1
Fecha
Fecha ex-dividendo
Tipo
Relación
Dec 22, 2023
Merger
2→1
Dec 22, 2023
Merger
2→1
Dec 22, 2023
Merger
2→1
Dec 22, 2023
Merger
2→1
